New data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical development programme, HCVerso™, have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 9–13 November in Boston, MA.
Seven abstracts will be presented at the meeting, most notably final results from the Phase IIb interferon-free SOUND-C2 trial of faldaprevir (formerly known as BI 201335) and BI 207127 with and without ribavirin.(1,2 )This study includes patients with the most common and most challenging type of HCV to cure, genotype-1, including patients with complete liver cirrhosis,(1) an advanced form of liver disease.
Through its robust clinical trial programme, Boehringer Ingelheim aims to find solutions to the real-life challenges faced by hepatitis C patients. Phase III trials investigating the interferon-free regimen will commence later this year.
Boehringer Ingelheim’s abstracts can be accessed through the AASLD website today, www.aasld.org.
- Soriano V. et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 ± ribavirin (RBV) in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: Results from the SOUND-C2 study. To be presented at AASLD 2012
- Zeuzem S. et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the nonnucleoside NS5B inhibitor BI 207127 ± ribavirin (R): Final results of SOUND-C2 and predictors of response. To be presented at AASLD 2012